Fulvestrant - Eagle Pharmaceuticals

Drug Profile

Fulvestrant - Eagle Pharmaceuticals

Alternative Names: Fulvestrant for injectable suspension - Eagle Pharmaceuticals

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 03 Nov 2017 Chemical structure information added
  • 02 Nov 2017 Eagle Pharmaceuticals plans a phase I trial for Breast cancer (In volunteers) in December 2017 (NCT03324061)
  • 01 Sep 2017 Preclinical trials in Breast cancer in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top